about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisFexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sicknessIdentification of an antimalarial synthetic trioxolane drug development candidateSpiroindolones, a potent compound class for the treatment of malariaStrong binding in the DNA minor groove by an aromatic diamidine with a shape that does not match the curvature of the groovePreclinical Evaluation of the Antifolate QN254, 5-Chloro- N'6'-(2,5-Dimethoxy-Benzyl)-Quinazoline-2,4,6-Triamine, as an Antimalarial Drug CandidateDesign, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI)Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductaseAnti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactonesAdenosine Kinase of T. b. Rhodesiense identified as the putative target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine using chemical proteomicsAdvancing drug innovation for neglected diseases-criteria for lead progressionGenetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and TrypanosomaEfficacy study of novel diamidine compounds in a Trypanosoma evansi goat modelPharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasisIsothermal microcalorimetry, a new tool to monitor drug action against Trypanosoma brucei and Plasmodium falciparumAgrochemicals against malaria, sleeping sickness, leishmaniasis and Chagas diseaseNaphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanismSafety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasisAquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprolChemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeysAntiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug RepositioningCharacterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling
P50
Q21144510-12F0FE1E-7B4C-4F9B-AA80-2EAEBCDF835AQ21144517-33E723C5-1751-48E5-AE85-4AD4642C8F4AQ22061876-519968B1-DFDA-4E40-A6D1-7469A4E8BBBBQ24606915-017F812D-76E8-4BC4-9A0D-83F01DD0AD8DQ27639964-ACF580C9-399E-4AD2-818E-8F983784FB66Q27660357-F8B71068-BD32-4334-8AE1-E1F5BD7FA51DQ27686782-B484B133-16F9-446F-99BE-CB95CAB714FCQ27690137-1E8AC0C7-48BE-4A65-8ADC-BD2FE6E5C101Q28201041-9CB6FC07-A558-4DCC-B64A-D8B363022896Q28475966-0611507E-F81A-4BCB-9A92-7651E718F8A9Q28475996-6D8B2C65-1E1A-45FF-A67A-9F2987773E69Q28478249-9AB6DEDD-3B2E-402C-A781-7BFD796F9794Q28478634-BB23827D-BB25-441D-9CF2-2DBF19E4BB0CQ28481509-9720878E-222E-45E4-9AEE-09DB6C03FA34Q28484117-7578171F-376D-4A8D-B653-56C53C543E19Q28484975-F7F7EDA4-C9C6-4E81-AEB7-3095EF5CA0F0Q28485165-28EEDFCB-3239-4050-9830-2F24F3F98FB8Q28533660-35145A30-F70B-42E7-887E-31C0E9689955Q28534313-4392B0D8-C64C-4FC8-A015-B990DEB73BECQ28543200-0453BAE8-2C7E-4639-9261-9FB7B9E964D6Q28547217-BD9FB8AA-5CFA-412C-9381-7D5FBF66D93CQ28554466-6CDDA571-0D2D-44FF-B22B-734EFAF2858F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Reto Brun
@ast
Reto Brun
@en
Reto Brun
@es
Reto Brun
@nl
Reto Brun
@sl
type
label
Reto Brun
@ast
Reto Brun
@en
Reto Brun
@es
Reto Brun
@nl
Reto Brun
@sl
prefLabel
Reto Brun
@ast
Reto Brun
@en
Reto Brun
@es
Reto Brun
@nl
Reto Brun
@sl